With an Ebola epidemic raging in West Africa, and one day after federal health officials confirmed the first case in the United States, West Haven vaccine developer Nanoviricides said Wednesday that it has restarted its anti-Ebola drug development program.
Nanoviricides said it has started synthesizing drug candidates, and plans to work with previous collaborators — who it did not name — to evaluate the drugs.
The company, which is also developing drugs for influenza, dengue and HIV, said its nanomedicine technology may be able to overcome Ebola’s fast mutations because it imitates the sites to which the virus binds.
Several efforts are underway to speed an Ebola vaccine to stem the outbreak in Africa.
The Associated Press reported that share prices of a handful of publicly traded vaccine makers jumped on the U.S. Center for Disease Control’s announcement Tuesday.
